Use of Saliva for COVID-19 Diagnosis

Use of Saliva for Diagnosis of SARS-CoV2 Infection

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04953039

Acronym

SALIVA-01

Enrollment

109

Registered

2021-07-07

Start date

2020-11-19

Completion date

2021-10-12

Last updated

2022-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-CoV2 Infection

Keywords

Salivary test

Brief summary

Aim of the study is to evaluate the presence of SARS-CoV2 RNA in the saliva of patients with suspected or confirmed COVID-19 in order to validate the analysis of this type of sample for the diagnosis of SARS-CoV2 infections.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients ≥ 18 years of age hospitalized in the COVID-19 wards of ASST Monza - San Gerardo Hospital with positive, weakly positive or negative nasopharyngeal swabs; initially assessed at the E.R.; symptomatic or asymptomatic with indication to hospitalization. * Informed consent freely granted and acquired before the start of the study.

Exclusion criteria

* Patients with significant clinical conditions which could interfere with the study in the opinion of the researchers.

Design outcomes

Primary

Measure	Time frame	Description
Presence of SARS-CoV2 RNA in the saliva of patient with suspected or confirmed COVID-19.	Up to 52 weeks	Positive - Negative

Countries

Italy

Outcome results